Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity is primarily operates through the region of United States.
| Website: | www.otonomy.com |
| Email: | ir@otonomy.com |
| Main Phone: | +1 619 323-2200 |
| Address: | 4796 Executive Drive |
| Address 2: | Suite 100 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NGS |
| CEO: | David A. Weber |
| Employees: | 49 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Otonomy (OTIC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of diseases and disorders of the ear. It
Full IPO calendar & reports HERE. In order of largest IPO first. (1) Based in San Diego, CA, Otonomy (OTIC) scheduled an $80 million IPO on the Nasdaq with a market
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity is primarily operates through the region of United States.
| Website: | www.otonomy.com |
| Email: | ir@otonomy.com |
| Main Phone: | +1 619 323-2200 |
| Address: | 4796 Executive Drive |
| Address 2: | Suite 100 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NGS |
| CEO: | David A. Weber |
| Employees: | 49 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Otonomy (OTIC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of diseases and disorders of the ear. It
Full IPO calendar & reports HERE. In order of largest IPO first. (1) Based in San Diego, CA, Otonomy (OTIC) scheduled an $80 million IPO on the Nasdaq with a market
| Last Price 3.60 | Change $ 0.07 | Change % 1.98 | Tick N/A |
| Bid 3.38 | Bid Size 500.00 | Ask 3.75 | Ask Size 500.00 |
| Open 3.51 | High 3.72 | Low 3.51 | Prev Close 3.53 |
| Last Trade | Volume 872,428 | 52 Wk Hi 4.89 | 52 Wk Low 1.53 |
| Market Cap 173.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 48,227,421.00 | EPS (TTM) -1.43 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 14 |
| Number of Buys | 0 | 1 |
| Number of Sells | 0 | 13 |
| Net Activity | 0 | -112373 |
| Last 10 Buys | Shares |
|---|---|
| Vickie L. Capps | 1,000 |
| Vickie L. Capps | 1,000 |
| Jay Lichter | 1,000 |
| Chau Q. Khuong | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Eric J. Loumeau | 1,000 |
| Eric J. Loumeau | 1,000 |
| Carl LeBel | 1,000 |
| Carl LeBel | 1,000 |
| Carl LeBel | 1,000 |
| Carl LeBel | 1,000 |
| Carl LeBel | 1,000 |
| Carl LeBel | 1,000 |
| Carl LeBel | 1,000 |
| Paul E. Cayer | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 15 | 15 | 15 | 15 |
| Low Target Price Estimate | 9 | 9 | 9 | 9 |
| Mean Target Price Estimate | 11.67 | 11.67 | 11.67 | 11.67 |
| Standard Deviation | 3.06 | 3.06 | 3.06 | 3.06 |
| Date of Most Recent Estimate | 05/10/18 | 05/10/18 | 05/10/18 | 05/10/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 10-Q | Quarterly report with a continuing view of a company's financial position | 63 | 2018-05-09 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-09 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 42 | 2018-04-27 |
| S-8 | Securities offered to employees under employee benefit plans | 9 | 2018-03-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 10 | 2018-03-08 |
| 10-K | Annual report with a comprehensive overview of the company | 112 | 2018-03-08 |
| SC 13G | Statement of beneficial ownership of common stock by certain persons | 5 | 2018-02-09 |
| SC 13G/A | Amendment to the SC 13G filing | 6 | 2018-02-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-02-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-02-05 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 0 |
| Mean Rec. | 2.33 | 2.33 | 2.33 | 1.5 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait